Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.41 |
| ▸ | HTR1A | P08908 | 9/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6604954 | 0.99 | HTR2C (0.48) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL6606751 | 0.81 | MEN1 (0.44) | — | |
| SCHEMBL15818392 | 0.71 | HTR2C (0.59) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| Hydrochloric Acid SCHEMBL7666084 | 0.70 | HTR2C (0.61) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL4431279 | 0.68 | HTR2C (0.55) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| Hydrochloric Acid SCHEMBL5729720 | 0.67 | HTR2C (0.56) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL30493303 | 0.66 | HTR2C (0.72) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL7676995 | 0.66 | HTR2C (0.53) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL27569963 | 0.66 | SLC6A2 (0.47) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL7670262 | 0.65 | HTR2C (0.56) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6365602-B1 | FOR THERAPY OF DEPRESSION, ANXIETY, ASTHMA, PAIN, INFLAMMATION, URINARY INCONTINENCE AND OTHER DISEASE CONDITIONS | ASTRA ZENECA AB (SE) | 2002-04-02 | — | — | US | disclosed |
| EP-1097137-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000002859-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | disclosed |